医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ImpediMed Vice President Dennis Schlaht Receives 2018 Advocate Award from Lymphatic Education & Research Network

2018年06月25日 PM11:00
このエントリーをはてなブックマークに追加


 

SANTA MONICA, Calif.

ImpediMed Limited (ASX: IPD), the global leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status, announces that Dennis Schlaht, senior vice president, R&D and Technology, received the 2018 Lymphatic Education & Research Network (LE&RN) Advocate Award at the annual 5K Run/Walk to Fight Lymphedema & Lymphatic Diseases. Schlaht was recognized for his contributions in raising awareness and funding for diseases that affect over 10 million Americans and up to 170 million worldwide.

“As a result of the commitment of people like Dennis Schlaht, this movement has gained significant momentum over the past few years,” says William Repicci, president and CEO, LE&RN. “An early corporate supporter and active participant in LE&RN and its events, Dennis has left a lasting impression on Run/Walk participants. His involvement is so valuable for patients who often feel isolated as they struggle with these diseases. Extraordinary individuals like Dennis are so deserving of the honors presented to them.”

LE&RN is an internationally recognized non-profit organization founded in 1998 to fight lymphatic diseases and lymphedema through education, research and advocacy. LE&RN spokesperson actor Kathy Bates hosted a cocktail reception for top fund raisers in conjunction with the event.

Schlaht says, “It is so gratifying to witness our progress and see our dreams becoming reality. It has been my honor to support the organization and shine a light on these diseases which have been largely ignored or misdiagnosed. At ImpediMed, their struggles are part of the passion that fuels our personal and professional commitment. We will continue to build public awareness, provide education and engage the healthcare community in changing the lives of all those who face the challenges of these diseases.”

About ImpediMed

Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications, including heart failure and lymphoedema, sold in select markets globally. Visit www.impedimed.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180625005716/en/

CONTACT

Media:
For ImpediMed
Laura Carabello,
201-641-1911 x12

lcarabello@cpronline.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 欧州委員会、未治療のCD30陽性ステージ4ホジキンリンパ腫成人患者に対する数十年ぶりの新規治療法となるアドセトリス(ブレンツキシマブ・ベドチン)とAVDの併用を承認
  • Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission
  • SpeeDx开发呼吸道病毒复合检测
  • 欧盟委员会核准ADCETRIS® (brentuximab vedotin)联合AVD用于既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者,这是数十年来首个新治疗方案
  • New Mallika Sherawat Billboards: ‘Go Vegan for Someone You Love’